MARKET

ACRV

ACRV

Acrivon Therapeutics, Inc.
NASDAQ
1.910
-0.070
-3.54%
After Hours: 1.920 +0.01 +0.52% 19:57 05/11 EDT
OPEN
1.990
PREV CLOSE
1.980
HIGH
1.990
LOW
1.890
VOLUME
549.44K
TURNOVER
--
52 WEEK HIGH
3.560
52 WEEK LOW
1.050
MARKET CAP
81.75M
P/E (TTM)
-0.9441
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACRV last week (0504-0508)?
Weekly Report · 1d ago
Weekly Report: what happened at ACRV last week (0427-0501)?
Weekly Report · 05/04 10:15
Weekly Report: what happened at ACRV last week (0420-0424)?
Weekly Report · 04/27 10:18
Weekly Report: what happened at ACRV last week (0413-0417)?
Weekly Report · 04/20 10:14
Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026
Benzinga · 04/17 20:03
Acrivon flags preclinical synergy data for ACR-368, ACR-2316 with PD-L1 blockade
PUBT · 04/17 20:00
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Barchart · 04/17 15:00
Acrivon Therapeutics grants new hire options to buy 111,150 shares under inducement plan
PUBT · 04/15 20:06
More
About ACRV
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Webull offers Acrivon Therapeutics Inc stock information, including NASDAQ: ACRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRV stock methods without spending real money on the virtual paper trading platform.